Selexys Pharmaceuticals Completes Series A Led by MPM Capital
Selexys Pharmaceuticals has completed a $23 million Series A equity financing, led by MPM Capital. Selexys has also entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease. Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $665 million.
20 September 2012•3 mins read
